Dale Bredesen, MD

Professor of Neurology
Easton Laboratories for Neurodegenerative Disease Research
David Geffen School of Medicine at UCLA, Los Angeles, CA
Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA

Dr. Bredesen received his undergraduate degree from Caltech, medical degree from Duke, and was Resident and Chief Resident in Neurology at UCSF, then postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner.  He was Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease.  His group has developed a new approach to the treatment of Alzheimer’s disease, and this approach has led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and early Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014 and 2016.  His book, The End of Alzheimer’s, is a New York Times Bestseller.